Lantern Pharma Inc.
LTRN
$2.51
$0.4521.85%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.65% | 7.29% | 12.67% | 16.62% | -40.36% |
| Total Depreciation and Amortization | -73.51% | 1,134.09% | 1,144.19% | 1,178.05% | 8.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.46% | 224.85% | -162.75% | -83.28% | 269.74% |
| Change in Net Operating Assets | -35.96% | 28.16% | 226.62% | -96.76% | 49.37% |
| Cash from Operations | 29.70% | 18.10% | 24.15% | -42.60% | -17.32% |
| Capital Expenditure | 100.00% | 80.00% | 100.00% | 45.45% | 39.22% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -149.39% | 767.59% | 1,916.58% | 684.93% | 1,220.44% |
| Cash from Investing | -149.43% | 771.45% | 1,877.93% | 682.40% | 1,245.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 7,998.33% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 7,998.33% | -- | -- | 100.00% |
| Foreign Exchange rate Adjustments | 104.46% | -101.85% | 146.90% | 128.57% | -1,300.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -570.37% | 147.77% | 94.12% | 68.34% | 83.72% |